New Recruiting Trial: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
WHY IT MATTERS
This trial targets newly diagnosed GBM patients with unmethylated MGMT and EGFRvIII mutations—a subgroup with historically poor prognosis—and offers access to a potentially more effective treatment combination before it becomes widely available.
Researchers are looking for patients with a specific type of brain cancer called glioblastoma (GBM) to test a new drug combination. The study will test a drug called silevertinib combined with temozolomide in patients whose tumors have certain genetic features (unmethylated MGMT and EGFRvIII). This is an early-stage study to see if this combination works better than current treatments.
NCT ID: NCT07326566 Title: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Status: RECRUITING Phase: PHASE2 Sponsor: Black Diamond Therapeutics, Inc. Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07326566 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you or a loved one has newly diagnosed GBM with unmethylated MGMT and EGFRvIII, contact the trial site listed on clinicaltrials.gov (NCT07326566) immediately to learn about enrollment—the trial is actively recruiting now.